Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cetylpyridinium chloride - ARMS Pharmaceutical

Drug Profile

Cetylpyridinium chloride - ARMS Pharmaceutical

Alternative Names: ARMS-I; CPC

Latest Information Update: 07 Apr 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ARMS Pharmaceutical
  • Developer ARMS Pharmaceutical; University Hospitals Cleveland Medical Center; University of Toledo
  • Class Antiseptics; Disinfectants; Pyridinium compounds; Small molecules
  • Mechanism of Action Cell membrane modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Respiratory tract infections
  • Preclinical COVID 2019 infections; Influenza virus infections

Most Recent Events

  • 02 Apr 2020 ARMS Pharmaceutical, University Hospitals Cleveland Medical Center and Case Western Reserve University plan the ARMS-I COVID Study in COVID-2019 infections (Prevention, Treatment) in USA (PO) in April 2020
  • 07 Mar 2017 Chemical structure information added
  • 06 Feb 2017 ARMS Pharmaceutical has patents pending for ARMS-I platform in USA, Europe, Japan, China, Brazil, India, Korea, Canada, Mexico, Israel (ARMS Pharmaceutical, February 2017)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top